ERBB2 and non-small cell lung carcinoma: Building on these positive outcomes, eight clinical trials are underway or planned to assess the therapeutic effect of SKB264, alone or in combination with other agents, in multiple advanced solid tumors, such as NSCLC, TNBC, and HR+/HER2- BC.